Cinclus Pharma

17.20 SEK

+1.18 %

Less than 1K followers

CINPHA

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+1.18 %

-1.38 %

+14.06 %

+9.69 %

-19.55 %

-12.41 %

-

-

-47.25 %

Cinclus Pharma is a Swedish pharmaceutical company in the clinical phase. The company is active in the development of molecules for the treatment of acid-related diseases. The company's leading drug candidate linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Cinclus Pharma was founded in 2014 and has its headquarters in Stockholm.

Market cap

815.15M SEK

Turnover

1.09M SEK

Revenue

4.58M

EBIT %

-3,703.93 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

19.1

2026

Extraordinary general meeting '26

18.2

2026

Annual report '25

13.5

2026

Interim report Q1'26

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release7 hours ago

Cinclus Pharma’s linaprazan glurate earns China’s National Reimbursement Listing and is set to launch in China in 2026

Regulatory press release7 hours ago

Cinclus Pharma recruits Magnus Christensen as new CFO

Regulatory press release8 hours ago

Notice of Extraordinary General Meeting in Cinclus Pharma Holding AB (publ)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release12/1/2025, 2:25 PM

Cinclus Pharma’s Nomination Committee proposes new representative for the company’s founders to the Board

Press release11/26/2025, 7:00 AM

Cinclus Pharma invites to KOL event: insights on clinical practice for erosive Gastroesophageal Reflux Disease (GERD) patients

Press release11/20/2025, 2:19 PM

Redeye: Cinclus Pharma (Q3 review) - Pivotal studies underway

Cinclus Pharma, Audiocast, Q3'25

Webcast11/20/2025, 9:00 AM

Cinclus Pharma, Audiocast, Q3'25

Regulatory press release11/20/2025, 7:00 AM

A positive start to the Phase III study

Regulatory press release11/20/2025, 7:00 AM

A positive start to the Phase III study

Regulatory press release11/18/2025, 7:00 AM

Cinclus Pharma's Nomination Committee for the 2026 Annual General Meeting appointed

Press release11/10/2025, 7:00 AM

Cinclus Pharma sponsors a scientific conference abstract highlighting the significant clinical and economic costs of PPI treatment failures in severe erosive GERD

Press release11/5/2025, 7:00 AM

Invitation to presentation of Cinclus Pharma’s third quarter report 2025

Press release11/4/2025, 7:00 AM

Cinclus Pharma to participate in upcoming investor conferences

Press release10/21/2025, 6:00 AM

Cinclus Pharma receives positive FDA feedback on CMC meeting

Press release10/7/2025, 6:55 AM

Cinclus Pharma doses first patient in Phase III study evaluating linaprazan glurate for the treatment of erosive gastroesophageal reflux disease

Press release9/23/2025, 6:00 AM

Cinclus Pharma to present linaprazan glurate data at the European Gastroenterology Week (UEGW)

Press release9/12/2025, 6:00 AM

Cinclus Pharma announces screening of first patient in HEEALING 1 Phase III trial evaluating linaprazan glurate for the treatment of erosive GERD

Regulatory press release8/29/2025, 5:30 AM

Cinclus Pharma to initiate HEEALING 1 Phase III study of linaprazan glurate in patients with Erosive Gastroesophageal Reflux Disease (GERD)

Cinclus Pharma, Audiocast, Q2'25

Webcast8/20/2025, 8:00 AM

Cinclus Pharma, Audiocast, Q2'25

Regulatory press release8/20/2025, 6:00 AM

Interim report January-June 2025 - Strengthened position for future value creation

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.